The Effect of Latanoprost Compared with Timolol in African-American, Asian, Caucasian, and Mexican Open-Angle Glaucoma or Ocular Hypertensive Patients
To access this article, please choose from the options below
Supported by Pharmacia Corporation, Peapack, New Jersey, USA. Katarina Hedman is employed by Pharmacia Diagnostics, Uppsala, Sweden, and Lill-Inger Larsson is employed by Pharmacia Corporation, Stockholm, Sweden. Neither of the authors reported any proprietary interest in the development or marketing of drugs used in the clinical trials subject to this article. Presented in part at the European Society of Ophthalmology meeting in Stockholm, Sweden, June 1999 and the 6th Congress of the European Glaucoma Society, UK, London, June 2000. The authors wish to thank Adam Taube, PhD, Department of Information Science–Statistics, Uppsala University, Uppsala, Sweden; Albert Alm, MD, Department of Neuroscience–Ophthalmology, Uppsala University Hospital, Uppsala, Sweden; and Berith Ahlsten, BSc, Hospital Pharmacy, Uppsala University Hospital, Uppsala, Sweden, for valuable contributions.
PII: S0039-6257(02)00310-7
© 2002 Elsevier Science Inc. All rights reserved.
